DRAGON: PHASE 1 TRIAL OF SRK-181, A LATENT TGF beta 1 INHIBITOR IN COMBINATION WITH ANTI-PD-(L)1 INHIBITORS FOR PATIENTS WITH SOLID TUMORS UNRESPONSIVE TO ANTI-PD-(L)1 THERAPY ALONE-MedSci.cn

DRAGON: PHASE 1 TRIAL OF SRK-181, A LATENT TGF beta 1 INHIBITOR IN COMBINATION WITH ANTI-PD-(L)1 INHIBITORS FOR PATIENTS WITH SOLID TUMORS UNRESPONSIVE TO ANTI-PD-(L)1 THERAPY ALONE

Gan, L; Bendell, J

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020; 8 (): A244

科室
- - 订阅+
  - 更多科室
工具
服务